

Quantity Limit

Ketorolac

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name	Dosage Form
ketorolac (all brands)	ketorolac	tablets
Sprix	ketorolac	nasal spray

Indications

FDA-approved Indications

Ketorolac Tablets

Carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

Ketorolac tromethamine tablets are indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of ketorolac tromethamine and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary.

The total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses. Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine tablet therapy is not to exceed 5 days.

Reference number(s)
233-H

Sprix

Sprix is indicated in adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level.

Limitations of Use

Sprix is not for use in pediatric patients less than 2 years of age.

Initial Limit Quantity

Limits should accumulate across all drugs and strengths up to highest quantity listed depending on the order the claims are processed. Accumulation does not apply if limit is coded for daily dose.

The duration of 25 days is used for a 30-day fill period to allow time for refill processing

These drugs are for short-term acute use; therefore, the intent is for prescriptions of the requested drug to be filled one month at a time; there should be no 3 month supplies filled.

Drug	1 Month Limit	3 Month Limit
ketorolac tablets	20 tablets / 25 days	Does Not Apply
Sprix nasal spray (ketorolac nasal spray)	5 bottles / 25 days	Does Not Apply

References

1. Ketorolac [package insert]. Parsippany, NJ: Teva Pharmaceuticals; July 2021.
2. Sprix [package insert]. Wayne, PA: Zyla Life Sciences US Inc.; April 2021.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed September 5, 2024.
4. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 09/05/2024).

Document History

Created: UM Development (DP) 03/1998

Revised: LS 03/2001; PJ 11/2002; MG 10/2003, 10/2004; NB 08/2005, 08/2006; CT 07/2007, 08/2008, 08/2009, 12/2009, 06/2010 (addition of Sprix), 06/2011, 03/2012, 01/2013, 01/2014; SF 01/2015; CT 01/2016 (no clinical changes); SF 01/2017 (no clinical changes); CF 09/2017 (no clinical changes); DS 09/2018 (no clinical changes); KC 09/2019 (no clinical changes); CJM 09/2020 (no clinical changes); PM 09/2021 (no clinical changes); DFW 09/2022 (no clinical changes); TM 09/2023 (no clinical changes); KMB 09/2024 (no clinical changes)

Reference number(s)
233-H

Reviewed: CRC 03/1998, 03/2001; 12/2002; 10/2003; CDPR/Medical Affairs MM 10/2004, 08/2005, 08/2006; WF 07/2007, 08/2008, 08/2009, 12/2009, 06/2010; KP 06/2011, 03/2012; LMS 01/2013; KP 01/2014; SES 01/2015; (CHART) 09/26/19; 09/24/20, 09/30/21, 09/22/2022, 09/28/2023, 09/26/2024

External Review: 05/2001; 02/2003; 12/2003; 12/2004; 12/2005; 12/2006, 02/2008, 12/2008, 10/2009, 10/2010, 10/2011, 08/2012, 06/2013, 06/2014, 04/2015, 04/2016, 04/2017, 02/2018, 02/2019, 02/2020, 12/2020, 12/2021, 12/2022, 12/2023, 12/2024